These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 16823938)
61. Effects of immunomodulators on the response induced by vaccines against autoimmune diseases. Marciani DJ Autoimmunity; 2017 Nov; 50(7):393-402. PubMed ID: 28906131 [TBL] [Abstract][Full Text] [Related]
62. Characterization of the in situ immunological responses to vaccine adjuvants. Horohov DW; Dunham J; Liu C; Betancourt A; Stewart JC; Page AE; Chambers TM Vet Immunol Immunopathol; 2015 Mar; 164(1-2):24-9. PubMed ID: 25619587 [TBL] [Abstract][Full Text] [Related]
63. Comparison of the adjuvant activity of emulsions with different physicochemical properties on the antibody response towards the venom of West African carpet viper (Echis ocellatus). Valverde JM; Rodríguez K; Herrera M; Segura Á; Vargas M; Villalta M; Montero M; Gutiérrez JM; León G Toxicon; 2017 Mar; 127():106-111. PubMed ID: 28088478 [TBL] [Abstract][Full Text] [Related]
64. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice. Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768 [TBL] [Abstract][Full Text] [Related]
65. Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines. Moyle PM Biotechnol Adv; 2017; 35(3):375-389. PubMed ID: 28288861 [TBL] [Abstract][Full Text] [Related]
66. A novel emulsion adjuvant increases the immunogenic responses and protective efficacy of an inactivated influenza vaccine in BALB/c mice. Wang S; Ke CW; Zou LR; Jing Z; Xie GX; Li X Intervirology; 2009; 52(5):252-7. PubMed ID: 19622895 [TBL] [Abstract][Full Text] [Related]
67. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vandepapelière P; Rehermann B; Koutsoukos M; Moris P; Garçon N; Wettendorff M; Leroux-Roels G Vaccine; 2005 Apr; 23(20):2591-601. PubMed ID: 15780441 [TBL] [Abstract][Full Text] [Related]
68. An immunopotentiator, ophiopogonin D, encapsulated in a nanoemulsion as a robust adjuvant to improve vaccine efficacy. Tong YN; Yang LY; Yang Y; Song Z; Peng LS; Gao JN; Zeng H; Zou QM; Sun HW; Mao XH Acta Biomater; 2018 Sep; 77():255-267. PubMed ID: 30031164 [TBL] [Abstract][Full Text] [Related]
69. Dose and timing requirements for immunogenicity of viral poultry vaccine antigen: investigations of emulsion-based depot function. Jansen T; Hofmans MP; Theelen MJ; Manders FG; Schijns VE Avian Pathol; 2007 Oct; 36(5):361-5. PubMed ID: 17899459 [TBL] [Abstract][Full Text] [Related]
70. Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits. Heldens JG; Glansbeek HL; Hilgers LA; Haenen B; Stittelaar KJ; Osterhaus AD; van den Bosch JF Vaccine; 2010 Nov; 28(51):8125-31. PubMed ID: 20950729 [TBL] [Abstract][Full Text] [Related]
71. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. Garçon N; Morel S; Didierlaurent A; Descamps D; Wettendorff M; Van Mechelen M BioDrugs; 2011 Aug; 25(4):217-26. PubMed ID: 21815697 [TBL] [Abstract][Full Text] [Related]
72. Adjuvants for veterinary vaccines--types and modes of action. Gerdts V Berl Munch Tierarztl Wochenschr; 2015; 128(11-12):456-63. PubMed ID: 26697712 [TBL] [Abstract][Full Text] [Related]
73. Current adjuvants and new perspectives in vaccine formulation. Montomoli E; Piccirella S; Khadang B; Mennitto E; Camerini R; De Rosa A Expert Rev Vaccines; 2011 Jul; 10(7):1053-61. PubMed ID: 21806399 [TBL] [Abstract][Full Text] [Related]
74. Evaluation of G2 Citric Acid-Based Dendrimer as an Adjuvant in Veterinary Rabies Vaccine. Asgary V; Shoari A; Afshar Moayad M; Shafiee Ardestani M; Bigdeli R; Ghazizadeh L; Khosravy MS; Panahnejad E; Janani A; Bashar R; Abedi M; Ahangari Cohan R Viral Immunol; 2018; 31(1):47-54. PubMed ID: 29328884 [TBL] [Abstract][Full Text] [Related]
75. Comparison of inactivated Newcastle disease viral vaccines containing different emulsion adjuvants. Brugh M; Stone HD; Lupton HW Am J Vet Res; 1983 Jan; 44(1):72-5. PubMed ID: 6824228 [TBL] [Abstract][Full Text] [Related]
76. Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants. Iyer V; Cayatte C; Guzman B; Schneider-Ohrum K; Matuszak R; Snell A; Rajani GM; McCarthy MP; Muralidhara B Hum Vaccin Immunother; 2015; 11(7):1853-64. PubMed ID: 26090563 [TBL] [Abstract][Full Text] [Related]
77. Structure- and oil type-based efficacy of emulsion adjuvants. Jansen T; Hofmans MP; Theelen MJ; Manders F; Schijns VE Vaccine; 2006 Jun; 24(26):5400-5. PubMed ID: 16675072 [TBL] [Abstract][Full Text] [Related]
78. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. Zhao G; Du L; Xiao W; Sun S; Lin Y; Chen M; Kou Z; He Y; Lustigman S; Jiang S; Zheng BJ; Zhou Y Vaccine; 2010 Oct; 28(44):7233-40. PubMed ID: 20732469 [TBL] [Abstract][Full Text] [Related]